Five years after its formation, the Clinical and Translational Science Award (CTSA) at the Univeristy of North Carolina at Chapel Hill (UNC), the North Carolina Translational and Clinical Sciences Institute (NC TraCS), has become the integrated, campus-wide home for clinical and translational research at UNC. The overall goal of this U54 Cooperative Agreement application is to combine the research strengths, resources and opportunities at UNC and new partner, RTI International (RTI), to build on the foundation established in the CTSA's last five years. NC TraCS .will work to improve human health by accelerating clinical and translational research from health science discovery to dissemination to patients and communities. NC TraCS will strive to overcome the well-documented barriers to the effective, sustained translation of research discovery along the translational research continuum by improving efficiency, training a research workforce and exporting successful, validated methods developed in NC TraCS to other CTSA institutions and the public. The proposed CTSA will specifically (1) amplify a thriving CTSA program to the point that it supports the full spectrum of clinical and translational research; (2) leverage CTSA resources and institutional strengths to create a critical, sustained focus on three strategic initiatives: (a) next-generation technologies to transform the very nature of clinical research and practice, (b) new paradigms and resources to accelerate drug development, and (c) robust comparative effectiveness research studies to provide definitive evidence of the benefits and harms of tests and treatments; and (3) train, support and incentivize the next generation of clinical and translational science researchers. These goals will be accomplished by three resources, six services, integrated and streamlined from the original 11, and the three strategic initiatives. UNC and RTI now have a unique set of research and training resources to support the full range of clinical and translational research, from basic science to clinical application to policy change. NC TraCS will leverage the opportunity of this CTSA application to garner >$60 million dollars in matching institutional support to extend our capabilities to meet the three aims. In partnership with RTI, NC TraCS will take advantage of the resources it has created and nourished during the past five years to quickly and effectively bring the fruits of research to patients across the state, as well as nationally through the CTSA Consortium.

Public Health Relevance

Researchers, clinicians and health policy experts have long lamented the well-documented lag between basic science discoveries and when those discoveries reach patients to treat them and make their lives better. The proposed UNC-RTI partnership in cooperation with the CTSA Consortium will help to ensure that patients will more quickly and effectively benefit from the results of biomedical research.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
3UL1TR001111-04S1
Application #
9326376
Study Section
Special Emphasis Panel (ZAI1-PTM-C (S1))
Program Officer
Wilde, David B
Project Start
2013-09-26
Project End
2018-04-30
Budget Start
2017-01-05
Budget End
2017-04-30
Support Year
4
Fiscal Year
2017
Total Cost
$168,804
Indirect Cost
$22,855
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Wang, Cheng; Mollan, Katie R; Hudgens, Michael G et al. (2018) Generalisability of an online randomised controlled trial: an empirical analysis. J Epidemiol Community Health 72:173-178
Mounsey, Louisa A; Deal, Allison M; Keith, Kevin C et al. (2018) Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies. Clin Breast Cancer 18:29-37
Turner, Kea; Trogdon, Justin G; Weinberger, Morris et al. (2018) Testing the organizational theory of innovation implementation effectiveness in a community pharmacy medication management program: a hurdle regression analysis. Implement Sci 13:105
Gartner, Danielle R; Doll, Kemi M; Hummer, Robert A et al. (2018) Contemporary Geographic Variation and Sociodemographic Correlates of Hysterectomy Rates Among Reproductive-Age Women. South Med J 111:585-590
Milko, Laura V; Rini, Christine; Lewis, Megan A et al. (2018) Evaluating parents' decisions about next-generation sequencing for their child in the NC NEXUS (North Carolina Newborn Exome Sequencing for Universal Screening) study: a randomized controlled trial protocol. Trials 19:344
Inscoe, Christina R; Platin, Enrique; Mauriello, Sally M et al. (2018) Characterization and preliminary imaging evaluation of a clinical prototype stationary intraoral tomosynthesis system. Med Phys 45:5172-5185
Nauck, Michael A; Jensen, Thomas Jon; Rosenkilde, Carina et al. (2018) Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. Diabetes Care 41:1663-1671
Lachiewicz, Anne M; van Duin, David (2018) Reply to Elamin et al. Clin Infect Dis 67:982-983
Thompson, Jessica D; Plummer, Prudence; Franz, Jason R (2018) Age and falls history effects on antagonist leg muscle coactivation during walking with balance perturbations. Clin Biomech (Bristol, Avon) 59:94-100
Kenney, Rachael M; Loeser, Adam; Whitman, Nathan A et al. (2018) Paper-based Transwell assays: an inexpensive alternative to study cellular invasion. Analyst :

Showing the most recent 10 out of 656 publications